2018
A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, Oliveira C, Meyer K, Grigorieva J, Asmellash SG, Roder J, Roder H. A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma. Cancer Immunology Research 2018, 6: 79-86. PMID: 29208646, DOI: 10.1158/2326-6066.cir-17-0412.Peer-Reviewed Original ResearchConceptsAcute phase reactantsCheckpoint inhibitorsOverall survivalPhase reactantsIpilimumab-treated patientsPD-1 blockadeTrials of nivolumabBetter overall survivalIndependent patient cohortsPretreatment serumPD-1Melanoma patientsValidation cohortMetastatic melanomaMultipeptide vaccinePatient cohortPooled analysisWorse outcomesClinical dataPatientsMultivariate analysisComplement cascadeMass spectrometry analysisNivolumabCohort
1992
Scatter factor and hepatocyte growth factor: activities, properties, and mechanism.
Bhargava M, Joseph A, Knesel J, Halaban R, Li Y, Pang S, Goldberg I, Setter E, Donovan M, Zarnegar R. Scatter factor and hepatocyte growth factor: activities, properties, and mechanism. Molecular Cancer Research 1992, 3: 11-20. PMID: 1534687.Peer-Reviewed Original ResearchConceptsHepatocyte growth factorScatter factorPartial amino acid sequence dataAmino acid sequence dataAmino acid sequenceFibroblast-derived proteinHuman smooth muscle cellsVascular endothelial cell typesEndothelial cell typesGrowth factorSignificant homologyPosttranslational modificationsSequence dataRapid phosphorylationAcid sequenceBiological activityTyrosine residuesProtein productsCohesive coloniesCommon antigenic determinantsCell typesSpecies-related differencesProteinSerum-derived proteinsHuman hepatocyte growth factor